for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chr Hansen Holding A/S

CHRH.CO

Latest Trade

504.80DKK

Change

-2.00(-0.39%)

Volume

220,748

Today's Range

496.40

 - 

508.00

52 Week Range

486.30

 - 

641.20

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Chr. Hansen And UPL Announce A Long-Term Collaboration

Oct 15 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::CHR. HANSEN AND UPL ANNOUNCE A LONG-TERM COLLABORATION TO DEVELOP AND COMMERCIALIZE....WILL DEVELOP BIOLOGICAL PRODUCTS BASED ON THEIR MICROBIAL CAPABILITIES.COMPANIES EXPECT FIRST REGISTRATIONS BY END OF 2022..UPL WILL REGISTER AND COMMERCIALIZE THESE PRODUCTS VIA ITS EXTENSIVE GLOBAL DISTRIBUTION NETWORK.

Chr. Hansen Q4 EBIT Ex-Items At EUR 84.2 Mln

Oct 14 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::REG-CHR. HANSEN ANNUAL REPORT 2020/21.OUTLOOK 2020/21: ORGANIC REVENUE GROWTH OF 5-8%.OUTLOOK 2020/21: EBIT MARGIN BEFORE SPECIAL ITEMS OF 27-28%.OUTLOOK 2020/21: FREE CASH FLOW BEFORE SPECIAL ITEMS OF EUR 140-170 MILLION.BOARD OF DIRECTORS PROPOSES AN ORDINARY DIVIDEND FOR 2020/21 OF EUR 0.87 (DKK 6.54) PER SHARE, FOR A TOTAL OF EUR 116 MILLION.Q4 REVENUE EUR 293.3 MILLION VERSUS COMPANY COMPILED CONSENSUS OF EUR 289 MILLION.Q4 EBIT EX-ITEMS EUR 84.2 MLN VS COMPANY COMPILED CONSENSUS OF EUR 86 MLN .Q4 PROFIT FROM CONTINUING OPERATIONS EUR 67.0 MILLION VERSUS COMPANY COMPILED CONSENSUS OF EUR 62 MILLION.LIMITED CUSTOMER ACCESS, DELAYED REGISTRATION TIMES, AND GENERAL MACROECONOMIC UNCERTAINTY RESTRAINED GROWTH OPPORTUNITIES, AND OUR HUMAN HEALTH BUSINESS DISAPPOINTED IN THE SECOND HALF OF THE YEAR DUE TO THE PART OF THE BUSINESS SERVING THE TRADITIONAL SALES CHANNELS.IN 2021/22, WE WILL BE FOCUSED ON COMMERCIAL EXECUTION AND ANCHORING THE NEW BUSINESSES, WHILE MAKING PROGRESS ON OUR 2025 STRATEGY PRIORITIES.LONG-TERM FINANCIAL AMBITIONS UNTIL 2024/25: INCREASE IN EBIT MARGIN BEFORE SPECIAL ITEMS OVER THE PERIOD.LONG-TERM FINANCIAL AMBITIONS UNTIL 2024/25: MID- TO HIGH SINGLE-DIGIT ORGANIC GROWTH, AVERAGED OVER THE PERIOD.LONG-TERM FINANCIAL AMBITIONS UNTIL 2024/25: AVERAGE GROWTH IN FREE CASH FLOW BEFORE SPECIAL ITEMS EXCEEDING THE AVERAGE GROWTH IN EBIT BEFORE SPECIAL ITEMS.

Chr.Hansen Holding Interim Report Q3 2020/21

July 8 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::REG-CHR. HANSEN HOLDING A/S INTERIM REPORT Q3 2020/21.REG-CHR. HANSEN HOLDING A/S INTERIM REPORT Q3 2020/21.CHR. HANSEN - Q3 REVENUE EUR 280.6 MILLION VERSUS COMPANY COMPILED CONSENSUS OF EUR 281 MILLION.CHR. HANSEN - OUTLOOK FOR 2020/21 ORGANIC REVENUE GROWTH 6-8%.CHR. HANSEN - Q3 EBIT EX-ITEMS EUR 82.4 MILLION VERSUS COMPANY COMPILED CONSENSUS OF EUR 78 MILLION.CHR. HANSEN - OUTLOOK 2020/21: EBIT MARGIN BEFORE SPECIAL ITEMS 27-28%.CHR. HANSEN - OUTLOOK 2020/21: FREE CASH FLOW BEFORE SPECIAL ITEMS, ACQUISITIONS AND DIVESTMENTS EUR 140-160 MILLION.CHR. HANSEN - Q3 PROFIT FROM CONTINUING OPERATIONS EUR 49.5 MILLION VERSUS COMPANY COMPILED CONSENSUS OF EUR 53 MILLION.CHR. HANSEN - Q3 ORGANIC GROWTH IMPACTED BY REDUCED CONTRIBUTION FROM EUR-BASED PRICING COMPARED TO H1.CHR. HANSEN - Q3 ORGANIC GROWTH IMPACTED BY HIGHER COMPARABLE, AS Q3 LAST YEAR WAS POSITIVELY IMPACTED BY COVID-19 RELATED CUSTOMER INVENTORY BUILD-UP.CHR. HANSEN - THE OVERALL MARKET FOR HUMAN HEALTH IS ESTIMATED TO HAVE GROWN BY 3-5% DURING THE FIRST NINE MONTHS OF 2020/21.CHR. HANSEN - ACCORDING TO THE COMPANY’S OWN ESTIMATES, THE END MARKETS FOR FERMENTED MILK DECLINED GLOBALLY IN THE FIRST NINE MONTHS OF 2020/21.CHR. HANSEN - THE MARKET FOR MICROBIAL-BASED SOLUTIONS FOR ANIMALS DEVELOPED FAVORABLY DURING THE FIRST NINE MONTHS OF 2020/21,.

Chr. Hansen To Declare An Extraordinary Dividend

May 17 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::TO DECLARE AN EXTRAORDINARY DIVIDEND OF EUR 116 MILLION, OR 6.54 DKK PER SHARE WITH AN EX-DIVIDEND DATE OF MAY 18, 2021.DIVIDEND WILL BE PAID ON MAY 20, 2021..EXTRAORDINARY DIVIDEND FOLLOWS COMPLETION OF DIVESTMENT OF NATURAL COLORS TO EQT.

Chr. Hansen Q2 EBIT Ex-Items Down At EUR 70.1 Mln

April 15 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::REG-CHR. HANSEN HOLDING A/S INTERIM REPORT Q2 2020/21.EXPECT THAT Q4 TO BE STRONGER OF TWO REMAINING QUARTERS, PRIMARILY AS Q3 OF LAST YEAR HAD A TAILWIND EFFECT FROM CUSTOMERS BUILDING COVID-19 RELATED SAFETY INVENTORIES.Q2 2020/21 ORGANIC SALES GROWTH WAS 10%, EQUALLY SPLIT BETWEEN VOLUME/MIX AND PRICE, AND DRIVEN BY HEALTH & NUTRITION WHICH DELIVERED 14% GROWTH WHILE FOOD CULTURES & ENZYMES DELIVERED 8% GROWTH.FULL-YEAR OUTLOOK FOR ORGANIC GROWTH ADJUSTED TO 6-8% (PREVIOUSLY 5-8%), FREE CASH FLOW NARROWED UPWARDS TO EUR 140-160 MIO, EBIT MARGIN GUIDANCE UNCHANGED, AND IMPACTS FROM ACQUISITIONS ALSO UNCHANGED FROM Q1.Q2 REVENUE EUR 260.0 MILLION VERSUS EUR 239.6 MILLION YEAR AGO.IN Q3 WE WILL BE LAUNCHING NEXT GENERATION OF BIOPROTECTION FOR FERMENTED MILKS AND CERTAIN CHEESES.Q2 EBIT EX-ITEMS EUR 70.1 MILLION VERSUS EUR 77.1 MILLION YEAR AGO.Q2 PROFIT FROM CONTINUING OPERATIONS EUR 46.1 MILLION VERSUS EUR 54.8 MILLION YEAR AGO.

Chr. Hansen Board Member Buys 1,000 Shares In Co

Jan 21 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::BOARD MEMBER KEVIN LANE BUYS 1,000 SHARES IN CO FOR DKK 550.28 PER SHARE.

Chr. Hansen Q1 EBIT Ex-Items At EUR 61.4 Mln

Jan 14 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::REG-CHR. HANSEN HOLDING A/S INTERIM REPORT Q1 2020/21.OUTLOOK FOR 2020/21 IS UNCHANGED ON ALL KEY PARAMETERS.Q1 2020/21 ORGANIC SALES GROWTH WAS 10%.CHR. HANSEN IS ON TRACK TO EXECUTE ON OUR 2025 STRATEGY AND BECOME A FOCUSED BIOSCIENCE COMPANY BASED ON A UNIQUE MICROBIAL AND FERMENTATION TECHNOLOGY PLATFORM.UNDERLYING EBIT MARGIN B.S.I. OF 28.5%.DIVESTMENT PROCESS OF NATURAL COLORS IS ALSO ON TRACK AND BUSINESS DELIVERED AS EXPECTED..THIS IS A YEAR OF TRANSITION, WHERE WE NEED TO SECURE A SUCCESFUL INTEGRATION OF ACQUIRED BUSINESSES..Q1 REVENUE EUR 243.5 MILLION (COMPANY CONSENSUS: EUR 257 MILLION).WE HAVE STARTED OUT STRONG, AND WE WILL ADDRESS ANY CHALLENGES THAT MAY ARISE IN THOSE PROCESSES HEAD ON AND WITH DETERMINATION..Q1 EBIT EX-ITEMS EUR 61.4 MILLION (COMPANY CONSENSUS: EUR 62.4 MILLION).Q1 PROFIT EUR 41.4 MILLION (COMPANY CONSENSUS: EUR 46.1 MILLION).DIVESTMENT OF NATURAL COLORS IS EXPECTED TO COMPLETE DURING THE SPRING OF 2021, AND UPON RECEIVING THE PROCEEDS THE BOARD OF DIRECTORS EXPECTS TO PAY OUT AN EXTRAORDINARY DIVIDEND AT LEAST EQUAL TO A NORMALIZED ORDINARY DIVIDEND FOR 2019/2.

Chr. Hansen - Q4 EBIT Ex-Items EUR 97.7 Million

Oct 8 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::REG-CHR. HANSEN HOLDING A/S FULL-YEAR REPORT - STATEMENT OF RESULTS 2019/20.REG-CHR. HANSEN HOLDING A/S FULL-YEAR REPORT - STATEMENT OF RESULTS 2019/20.CHR. HANSEN - WE HAVE A CAUTIOUS OUTLOOK FOR 2020/21, GIVEN UNCERTAINTIES THAT COVID-19 STILL CREATES.CHR. HANSEN - OUTLOOK 2020/21: WE EXPECT AN ORGANIC GROWTH RATE OF 5-8%, IN LINE WITH OUR LONG-TERM AMBITION, WITH HIGHEST CONTRIBUTION FROM HEALTH & NUTRITION.CHR. HANSEN - OUTLOOK 2020/21: WE EXPECT AN EBIT MARGIN BEFORE SPECIAL ITEMS OF 27-28%, GIVEN HEADWINDS FROM CURRENCIES, A NORMALIZATION OF COST BASE, AND SLIGHT HEADWIND FROM PORTFOLIO CHANGES.CHR. HANSEN - WE REMAIN FIRMLY COMMITTED TO OUR LONG-TERM AMBITION OF DELIVERING UNDERLYING EBIT MARGIN EXPANSION BY 2025.CHR. HANSEN - ORGANIC GROWTH ACCELERATED IN Q4, DRIVEN BY HEALTH & NUTRITION WHICH DELIVERED IMPRESSIVE 18% GROWTH.CHR. HANSEN - Q4 REVENUE EUR 254.3 MILLION VERSUS EUR 249.0 MILLION YEAR AGO.CHR. HANSEN - Q4 EBIT EX-ITEMS EUR 97.7 MILLION VERSUS EUR 94.3 MILLION YEAR AGO.CHR. HANSEN - FOR 2020/21, ORGANIC REVENUE GROWTH IS EXPECTED TO BE 5-8%, WITH THE HIGHEST CONTRIBUTION FROM HEALTH & NUTRITION.CHR. HANSEN - Q4 PROFIT EUR 66.2 MILLION VERSUS EUR 74.6 MILLION YEAR AGO.CHR. HANSEN - OUTLOOK 2020/21: EBIT MARGIN B.S.I. IS EXPECTED TO BE 27-28%..CHR. HANSEN - OUTLOOK 2020/21: FREE CASH FLOW BEFORE ACQUISITIONS & DIVESTMENTS AND SPECIAL ITEMS IS EXPECTED TO BE EUR 120-160 MILLION..

Chr Hansen Agrees To Divest Its Natural Colors Business To EQT

Sept 25 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::REG-CHR. HANSEN HOLDING A/S ENTERS INTO A DEFINITIVE AGREEMENT TO DIVEST ITS NATURAL COLORS BUSINESS TO EQT.CHR. HANSEN - DIVEST ITS NATURAL COLORS BUSINESS TO EQT IX FUND FOR A CASH CONSIDERATION OF 800 EUR MILLION ON CASH AND DEBT FREE BASIS.CHR. HANSEN - TRANSACTION IS EXPECTED TO CLOSE DURING SPRING OF 2021, SUBJECT TO REGULATORY APPROVALS.

Chr. Hansen Launches 2025 Strategy, Ambition To Create Differentiated Bioscience Leader

Aug 24 (Reuters) - Chr Hansen Holding A/S <CHRH.CO>::REG-CHR. HANSEN LAUNCHES 2025 STRATEGY WITH THE AMBITION TO CREATE A DIFFERENTIATED BIOSCIENCE LEADER TO IMPROVE FOOD AND HEALTH FOR A SUSTAINABLE FUTURE.RELEASED ITS 2025 STRATEGY WITH AMBITION TO CREATE A DIFFERENTIATED BIOSCIENCE COMPANY WITH FOCUS ON ITS MICROBIAL AND FERMENTATION TECHNOLOGY PLATFORMS PUTTING FOOD CULTURES & ENZYMES AND HEALTH & NUTRITION AT CENTER OF ITS NEW STRATEGY.NEW LONG-TERM FINANCIAL AND NON-FINANCIAL AMBITIONS UNTIL 2024/25.TO FOCUS INVESTMENTS ON MICROBIAL PLATFORM GOING FORWARD; STRATEGIC REVIEW OF NATURAL COLORS PROGRESSING WELL.AVERAGE GROWTH IN FREE CASH FLOW BEFORE ACQUISITIONS AND SPECIAL ITEMS IS EXPECTED TO EXCEED AVERAGE ABSOLUTE EBIT GROWTH.LONG-TERM FINANCIAL AMBITION IS TO DELIVER MID- TO HIGH SINGLE-DIGIT ORGANIC GROWTH, AVERAGED OVER PERIOD.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up